News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘Lymphoma’ clear

  • The Leukemia & Lymphoma Society and Dana-Farber joined together to establish the Blood Cancer Research Partnership, an innovative program bringing together a network of sites for clinical trial testing of blood cancer therapies in community oncology settings across the country.

Tags: Leukemia, Lymphoma

  • A new Dana-Farber study shows a “big picture” view of an overactive B cell receptor (BCR) signaling pathway that drives about one-third of Diffuse Large B-Cell Lymphomas, which could lead to more promising genetic targets for drug development.

Tags: Lymphoma

  • Dana-Farber researchers found an experimental drug blocked vulnerable cell growth pathways in a diverse group of aggressive B cell lymphomas, suggesting a potential new avenue for treating the most common type of non-Hodgkin lymphoma.

Tags: Lymphoma

  • Dana-Farber scientists have discovered the mechanism behind thalidomide's cancer-killing properties, which could aid development of safer versions and a new class of cancer drugs.

Tags: BasicResearch, MultipleMyeloma, Lymphoma

  • Scientists at Dana-Farber Cancer Institute have identified a gene mutation that underlies the vast majority of cases of Waldenström's macroglobulinemia, a rare form of lymphoma that has eluded all previous efforts to find a genetic cause.

Tags: BasicResearch, Lymphoma

  • Dana-Farber scientists have identified a protein that prevents the body's immune system from recognizing and attacking Hodgkin lymphoma cells. Based on this finding, the researchers are now investigating targeted therapies to disable this molecular "bodyguard" and boost a patient's ability to fight the blood cancer.

Tags: BasicResearch, ImmuneSystem, Lymphoma

  • Dana-Farber researchers have found a genetic signature in tumors to help them determine if diffuse large B cell lymphoma patients will benefit more from traditional therapies or targeted therapies.

Tags: BasicResearch, Lymphoma

  • Researchers at Dana-Farber/Children's Hospital Cancer Center have created a peptide that overcomes drug resistance and reactivates programmed cell death in recurrent blood cancers.

Tags: chemotherapy, DrugResistance, Leukemia, Lymphoma

  • Eighty-seven percent of Hodgkin lymphoma patients who participated in an early-phase immunotherapy clinical trial experienced cancer remission.

Tags: Lymphoma, Immunotherapy

  • Dana-Farber researchers identify a specific mutation that switches on Waldenström's Macroglobulinemia in one-third of patients, and a drug that targets the mutation — which could lead to better treatments for those patients.

Tags: Genetics, Lymphoma

Showing 1-10 of 15 items